Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 8/20 | 0.42 |
| ▸ | PYGM | P11217 | 6/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 9/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840482 | 0.88 | PYGL (0.40) | PYGLPYGMCRBNDDB1KDM4E | |
| SCHEMBL2842186 | 0.82 | EPHX2 (0.46) | PYGLPYGMCRBNBRD4 | |
| SCHEMBL2843061 | 0.81 | CTSK (0.42) | — | |
| SCHEMBL2837968 | 0.80 | LARS1 (0.37) | PYGLPYGMCRBN | |
| SCHEMBL27798571 | 0.78 | EPHX2 (0.40) | PYGLPYGMCRBNDDB1BRD4 | |
| SCHEMBL3948178 | 0.78 | PYGL (0.42) | PYGLPYGMCRBNDDB1KDM4E | |
| SCHEMBL25329367 | 0.77 | PYGL (0.64) | PYGLPYGMBRD4 | |
| SCHEMBL15541576 | 0.77 | PYGL (0.64) | PYGLPYGMBRD4 | |
| SCHEMBL29900499 | 0.77 | PYGL (0.64) | PYGLPYGMBRD4 | |
| SCHEMBL7344228 | 0.76 | EPHX2 (0.41) | PYGLPYGMCRBNKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2241564-B1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARM CO LTD (JP) | 2014-04-30 | — | — | EP | disclosed |
| US-8501772-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20130012537-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-10 | — | — | US | disclosed |
| US-8299255-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20100317693-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD (JP) | 2010-12-16 | — | — | US | disclosed |
| EP-2241564-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012537-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | MC2R, GHRHR, REN | PYGL 302/4885PYGM 305/4885CRBN 2656/4885 |
| US-20100317693-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | GHSR, GHRHR, GNRHR | PYGL 1140/4885PYGM 227/4885CRBN 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.